Multiple Studies At American Urological Association Annual Meeting Highlight Accuracy, Broad Applicability Of Genomedx's Decipher Test For Prostate Cancer

SAN DIEGO, May 15, 2015 /PRNewswire/ -- GenomeDx Biosciences announced that three abstracts presented today at the American Urological Association Annual Meeting in New Orleans featuring the Decipher® Prostate Cancer Classifier, a genomic test for prostate cancer, demonstrate the ability of Decipher to accurately predict risk based on unique genetic signatures in various patient populations.

"These data contribute to our expanding body of knowledge demonstrating that Decipher is highly predictive of cancer progression in men with prostate cancer," said Doug Dolginow, M.D., chief executive officer of GenomeDx. "Cancer is a genetic disease, and patients' unique genomic signatures are identifiable using our Decipher test. Aggressive cancer has a different genomic signature than low-risk prostate cancer, and our test can use that information to better classify patients and help physicians make treatment decisions."

Ashley Ross, M.D., of the Brady Urological Institute at Johns Hopkins School of Medicine, presented a study titled "Validation of the Decipher® Prostate Cancer Classifier in Intermediate to High Risk Men Treated with Radical Prostatectomy but Without Additional Therapy Upon PSA Rise," showing that an elevated Decipher score was predictive of metastasis. Decipher was able to predict metastasis free survival at 10 years in a natural history cohort of 260 intermediate and high-risk men.  In the study, the Decipher score was significantly higher among men experiencing metastatic progression compared to those who did not progress during follow up (0.47 vs 0.28 respectively p<0.001).

Michael Johnson, M.D., of Johns Hopkins, presented a study, titled "Evaluation of genomic signatures in intermediate to high risk men treated with radical prostatectomy but without additional therapy upon PSA rise," that compared four previously validated prognostic genomic signatures, including approximations of two commercially available tests, in 260 prostate cancer patients. The four signatures evaluated were Decipher, Penney, cell cycle progression (CCP) and genomic prostate score (GPS), and overall, the Decipher and Penney signatures had the strongest correlation to metastasis. ROC analysis for the survival data for metastasis 10 years following prostate surgery was 0.76, 0.74, 0.62 and 0.62 for Decipher, Penney, CCP and GPS, respectively.

Dr. Johnson also presented a study, titled "A novel biomarker signature which may predict aggressive disease in African-American men with prostate cancer," that evaluated differences in genetic signatures of prostate cancer in African American and European American men. The study validated Decipher's ability to predict metastasis within 5 years after radical prostatectomy in both African American (n = 154, AUC 0.78) and European American men (n = 243, AUC 0.88).

Two additional abstracts of Decipher in men with prostate cancer were presented at AUA, including a study detailing a genome-scale analysis of prostate cancer between African American and European American men, and a study of 1,577 men evaluating molecular subtypes of prostate cancer based on whole transcriptome profiling and their clinical associations.

About Decipher^®

The Decipher^® Prostate Cancer Classifier is a highly validated and commercially available genomic test for men with intermediate and high risk prostate cancer. Decipher predicts cancer aggressiveness by looking for a unique genomic signature comprised of a validated series of biomarkers associated with metastatic disease. Adding truly unique information to the treatment decision-making process, Decipher generates a risk result that is completely independent and distinct from PSA, Gleason score and other clinical risk factors. Clinical studies from leading cancer centers published in over a dozen medical journals demonstrate that Decipher can accurately predict metastatic disease, which men may benefit from radiation therapy following prostate surgery, and can lead to significant cost-savings for healthcare systems. Decipher was developed in partnership with the Mayo Clinic.

Decipher is covered by Medicare and multiple private insurance plans and is available to eligible US patients through their physicians.

Learn more at: www.DecipherTest.com and follow Decipher on Twitter at @DecipherTest and on Facebook.

About GenomeDx Biosciences

GenomeDx Biosciences is focused on transforming cancer patient care by putting usable genomic information in the hands of patients and their physicians. GenomeDx is developing and commercializing Decipher^®, a highly validated genomic test for predicting metastatic disease in men with prostate cancer. In partnership with leading medical centers, the company has assembled the largest genomic catalogue of prostate cancer tumors in the world, representing billions of data points and more than 20 years of prostate cancer research expertise. Using advanced cloud-based bioinformatics, GenomeDx mines the genomic data to develop proprietary tests that address key clinical questions in cancer patient management. GenomeDx has partnered to share genomic data with leading clinician-scientists worldwide to collaboratively enrich the knowledge and understanding of urologic cancers for the goal of improving global cancer patient care. GenomeDx is based in San Diego, California and Vancouver, British Columbia.

Learn more at www.genomedx.com and follow us on Twitter at @GenomeDx, Facebook, LinkedIn and YouTube.

Media Contact:
Ian Stone
Canale Communications
619-849-5388
ian@canalecomm.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/multiple-studies-at-american-urological-association-annual-meeting-highlight-accuracy-broad-applicability-of-genomedxs-decipher-test-for-prostate-cancer-300083981.html

SOURCE GenomeDx Biosciences